huberman glp-1 Neuroscientist Dr Andrew discusses the potential use of low-dose receptor agonists for cognitive well-being and neuroprotection. >> See comments 👇 andrew huberman glp 1 New

CagriSema is an investigational combination therapy of cagrilintide and semaglutide being developed for weight management and type 2 diabetes

Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S

It is not a drug, supplement, cosmetic, or medical product, none of its four peptides is FDA-approved as a drug, and it is not intended for human or veterinary use

An Arabidopsis cytokinin-modifying glycosyltransferase UGT76C2 improves drought and salt tolerance in rice

Studies indicate improvements in inflammatory markers, though again, distinguishing direct anti-inflammatory effects from those secondary to metabolic improvement remains challenging